This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
  • 00
  • 00
  • 00
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Biomissile Pharmaceuticals


Unleashing the potential of our fully human Domain Antibody (UDAB) to combat diseases is at the core of Biomissile's mission. We specialize in discovering and developing multi-specific therapeutic antibodies, particularly for diseases lacking effective treatments. Our cutting-edge fully human antibody discovery and optimization platforms enable us to swiftly produce multi-specific antibodies with exceptional developability profiles.
With operations spanning three locations - Shanghai (R&D Center), Suzhou (GMP Facility), and Boston (BD & Clinical Trials) - we are strategically positioned to drive innovation in the field.
Biomissile boasts five proprietary Antibody Discovery & Optimization Platform Technologies:
1) Fully Human Domain Antibody Display Platform (UDAB)2) Fully Human Domain Antibody-based Multi-specifics Platform (UDAB-M)3) Fully Human Phage Display Platform (U-Phage)4) Fully Human Yeast Display Platform (U-Yeast)5) Fully Human Mammalian Display Platform (U-Mamm)
In our latest breakthrough, we've pioneered an inhalable technology designed to safely and efficiently deliver UDAB molecules to the respiratory system and lungs. This marks a significant stride towards enhanced treatment modalities.